Redefine Surgery, a medical technology company building physical artificial intelligence for surgery, has closed an oversubscribed pre-seed financing round, bringing its total capital raised to $10 million. The round was backed predominantly by surgeon investors and will support continued development of the company's surgical intelligence platform as it moves toward commercialization. The company also announced that Catalyst OrthoScience has joined as a Founding Partner to develop surgical intelligence for shoulder arthroplasty.
Funding Details and Surgeon-Led Backing
Redefine Surgery said the pre-seed round was oversubscribed, reflecting strong interest from clinicians who will use the technology in practice. The financing brings the company's total capital raised to $10 million and will be directed toward advancing its platform toward regulatory readiness and commercial use. Surgeon investors played a central role in shaping the company's approach to surgical intelligence, according to the announcement.
Catalyst OrthoScience Partnership
Catalyst OrthoScience, a private medical technology company dedicated exclusively to shoulder replacement, has joined Redefine Surgery as a Founding Partner. The companies plan to develop an integrated surgical intelligence ecosystem that connects data, decisions, and outcomes across shoulder replacement procedures. Their shared objective is to improve procedural efficiency, consistency, and value for providers and patients.
Executive Perspective
Peter Verrillo, CEO and Co-Founder of Redefine Surgery, described the milestones as important steps toward bringing surgical intelligence into everyday practice. He noted that surgeon investors helped shape the company's direction and that Catalyst shares its belief in addressing the full episode of care, from planning and guidance to learning from each procedure. Verrillo added that the goal is to put that knowledge to work for surgical teams while keeping surgeons in control.
Platform Vision and Collaborative Intelligence
Redefine's platform is designed to be portable, open, and adaptable across anatomies, instruments, and surgical workflows, with an initial focus on orthopedic surgery. Its computer vision technology is being developed to help machines see and understand surgery, creating an intelligence layer for real-time guidance, smarter instruments, and robotic assistance. The company refers to this approach as Collaborative Surgical Intelligence, intended to make expert surgical technique more accessible through the tools surgical teams use.
Clinical Perspective
Dr. Anthony Miniaci, MD, FRCSC, President of the American Shoulder and Elbow Surgeons, said the next generation of surgical guidance will be an intelligent partner and collaborator to the surgeon. He explained that such technology could understand anatomy, help optimize incisions and surgical exposure, and optimize implant position based on a personalized plan for each patient. The goal is to move beyond navigating an implant to technology that understands the entire procedure and supports consistent outcomes.
Clinical Engagement and Next Steps
Redefine is showcasing its technology this week at the International Congress of Shoulder and Elbow Surgeons in Vancouver, following a presentation at the American Academy of Orthopaedic Surgeons earlier this year. The company is expanding clinical collaboration beyond its core network of more than 25 surgeon advisors and capturing procedures across multiple surgical specialties to train and validate its proprietary AI models. Redefine stated that its platform remains under development, with commercialization subject to applicable regulatory clearance and product readiness.
Company Background
Redefine Surgery is building Physical AI for surgery and launching first in orthopedic surgery, where it aims to provide a more accessible alternative to conventional robotic surgery. Catalyst OrthoScience is a private medical technology company dedicated exclusively to shoulder replacement and was founded by orthopedic surgeon Dr. Steven Goldberg. The two companies will combine Redefine's vision and AI platform with Catalyst's shoulder arthroplasty expertise to support a shared surgical intelligence ecosystem.
Redefine Surgery's oversubscribed round and its partnership with Catalyst OrthoScience underscore growing interest in artificial intelligence tools that support surgeons rather than replace their judgment. The company plans to use the funding to advance a platform that learns from real-world surgical experience and helps inform better decisions over time. As development progresses, regulatory clearance and clinical execution will be critical milestones on the path to commercialization.